{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=4&sponsor=AbbVie", "query": { "sponsor": "AbbVie", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 816, "total_pages": 82, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=5&sponsor=AbbVie&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=AbbVie&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T00:50:28.835Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07414784", "title": "A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "ABBV-295", "type": "DRUG" }, { "name": "Levonorgestrel/Ethinyl Estradiol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 20, "start_date": "2026-02-11", "completion_date": "2026-08-04", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-23T00:50:28.835Z", "location_count": 2, "location_summary": "Anaheim, California • Grayslake, Illinois", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Grayslake", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07414784" }, { "nct_id": "NCT03875508", "title": "A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" }, { "name": "Autoinjector", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "2019-06-04", "completion_date": "2020-08-25", "has_results": true, "last_update_posted_date": "2021-05-11", "last_synced_at": "2026-10-23T00:50:28.835Z", "location_count": 26, "location_summary": "Glendale, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 22 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03875508" }, { "nct_id": "NCT02065375", "title": "RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Inflammation and Pain Following Ocular Surgery" ], "interventions": [ { "name": "Omaveloxolone Ophthalmic Suspension 1.0%", "type": "DRUG" }, { "name": "Omaveloxolone Opthalmic Suspension 0.5%", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "2014-02-28", "completion_date": "2014-09-30", "has_results": true, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-10-23T00:50:28.835Z", "location_count": 6, "location_summary": "Garden Grove, California • Fort Myers, Florida • Kansas City, Missouri + 3 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Elizabeth City", "state": "North Carolina" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02065375" }, { "nct_id": "NCT06390319", "title": "Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T-cell Acute Lymphoblastic Leukemia", "T-cell Lymphoma", "Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Calaspargase pegol", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 100, "start_date": "2024-12-27", "completion_date": "2033-12", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-23T00:50:28.835Z", "location_count": 4, "location_summary": "San Diego, California • Charlotte, North Carolina • Tulsa, Oklahoma + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Tulsa", "state": "Oklahoma" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06390319" }, { "nct_id": "NCT05292664", "title": "Venetoclax Basket Trial for High Risk Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndromes, de Novo", "Myelodysplastic Syndromes, Secondary", "Myelodysplastic Syndromes, Previously Treated", "Treatment-Related Acute Myeloid Leukemia", "Therapy-Related Myelodysplastic Syndrome", "Acute Lymphoblastic Leukemia, in Relapse", "Acute Lymphoblastic Leukemia With Failed Remission", "Lymphoblastic Lymphoma, in Relapse", "Lymphoblastic Lymphoma, Refractory", "Acute Leukemia of Ambiguous Lineage in Relapse", "Acute Leukemia of Ambiguous Lineage" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Dexrazoxane", "type": "DRUG" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Erwinia asparaginase", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andrew E. Place, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "40 Years", "sex": "ALL", "summary": "1 Year to 40 Years" }, "enrollment_count": 30, "start_date": "2023-03-29", "completion_date": "2030-07-02", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-10-23T00:50:28.835Z", "location_count": 5, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05292664" }, { "nct_id": "NCT03071757", "title": "A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-368", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2017-03-21", "completion_date": "2022-04-13", "has_results": false, "last_update_posted_date": "2022-04-28", "last_synced_at": "2026-10-23T00:50:28.835Z", "location_count": 10, "location_summary": "La Jolla, California • Sacramento, California • Stanford, California + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03071757" }, { "nct_id": "NCT04611230", "title": "A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2)" ], "interventions": [], "intervention_types": [], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1007, "start_date": "2020-11-05", "completion_date": "2021-10-27", "has_results": false, "last_update_posted_date": "2022-10-10", "last_synced_at": "2026-10-23T00:50:28.835Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04611230" }, { "nct_id": "NCT07361367", "title": "A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "ABBV-722", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 11, "start_date": "2026-01-15", "completion_date": "2026-03-23", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-10-23T00:50:28.835Z", "location_count": 1, "location_summary": "Grayslake, Illinois", "locations": [ { "city": "Grayslake", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07361367" }, { "nct_id": "NCT04912063", "title": "Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndrome (MDS)" ], "interventions": [ { "name": "Lemzoparlimab", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-06-25", "completion_date": "2023-05-09", "has_results": false, "last_update_posted_date": "2024-02-26", "last_synced_at": "2026-10-23T00:50:28.835Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Louisville, Kentucky • Boston, Massachusetts + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04912063" }, { "nct_id": "NCT06256367", "title": "Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bipolar I Disorder" ], "interventions": [], "intervention_types": [], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2024-04-18", "completion_date": "2026-01-23", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-23T00:50:28.835Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Sacramento, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Cromwell", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06256367" } ] }